Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.34 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.30 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.30 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24260750 | 0.79 | KDM2B (0.39) | KDM2B | |
| SCHEMBL13131030 | 0.76 | SIGMAR1 (0.35) | SIGMAR1GRIN2DGRIN3BCHRM2CHRM1 | |
| SCHEMBL11916112 | 0.75 | SIGMAR1 (0.42) | SIGMAR1 | |
| SCHEMBL117945 | 0.73 | SIGMAR1 (0.41) | SIGMAR1 | |
| SCHEMBL19959061 | 0.73 | GRIN2D (0.35) | GRIN2DGRIN3BCHRM2CHRM1OPRM1 | |
| SCHEMBL24260751 | 0.73 | HTR6 (0.38) | KDM2B | |
| SCHEMBL22060207 | 0.73 | — | — | |
| SCHEMBL14996481 | 0.71 | SIGMAR1 (0.33) | SIGMAR1 | |
| SCHEMBL14155850 | 0.71 | SIGMAR1 (0.51) | SIGMAR1 | |
| SCHEMBL4440912 | 0.71 | SIGMAR1 (0.47) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202354-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-20180022707-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-01-25 | — | — | US | disclosed |
| US-20180022707-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180022707-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KDM1B, KDM6B, KDM2B | KDM2B 3/4885SIGMAR1 3301/4885GRIN2D 2964/4885 |
| US-10202354-B2 | Therapeutic compounds and uses thereof | KDM1B, KDM6B, KDM2B | KDM2B 3/4885SIGMAR1 3301/4885GRIN2D 2964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.